Chào mừng trở lại
Tham gia Cointime
Đăng nhập với email
Đăng nhập với
Đăng ký
CARsgen Therapeutics
About
CARsgen is a leading immunotherapy company focused on the development of new chimeric antigen receptor
- 501 - 1000
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $30M
- Industries
- Health Diagnostics,Medical,Therapeutics
- Founded date
- Nov 1, 2014
- Number Of Employee
- 501 - 1000
- Operating Status
- Active
CARsgen is a leading clinical-stage immunotherapy company focused on the development of new chimeric antigen receptor T (CAR-T) cell therapeutics for liver, lung, stomach and brain cancers. The company has partnership with Shanghai Cancer Institute and Shanghai Renji Hospital. The company is leading the first tier of CAR-T development, by completing World’s first hepatocellular carcinoma (HCC) and China’s exclusive glioblastoma multiforme (GBM) dose ascending injection tests. Funded by leading venture capital firm BVCF, CARsgen is well-positioned to bring a novel cancer therapeutics to the market in China and worldwide.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Nov 2, 2020 | Series C | $186M | 1 | — | — | Detail |
| Mar 2, 2018 | Series C | $60M | 1 | — | — | Detail |
| Jan 25, 2016 | Series B | $30M | 2 |
|
— | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Lilly Asia Ventures
|
— | Series C |
|
|
— | Series C |
|
|
— | Series B |
